AIM ImmunoTech (AIM) Total Liabilities (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Total Liabilities came in at $6.5 million in Q1 2026, down 36.07% YoY from $10.1 million in Q1 2025, and down 58.5% on a QoQ basis from $15.6 million in Q4 2025.
AIM ImmunoTech (AIM) Total Liabilities (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Total Liabilities data on file, last reported at $6.5 million in Q1 2026.
- Quarterly Total Liabilities fell 36.07% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 36.07% YoY) and the FY2025 annual result came in at $15.6 million, up 56.75% from the prior year.
- Total Liabilities fell to $6.5 million in Q1 2026, from $15.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $54.2 million in Q1 2022 to a low of $2.0 million in Q4 2022.
- A 5-year average of $21.0 million and a median of $11.4 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities plunged 96.5% — and 2023, when it soared 352.82%.
- Tracing AIM's Total Liabilities over 5 years: stood at $2.0 million in 2022, then soared by 352.82% to $9.1 million in 2023, then rose by 8.56% to $9.9 million in 2024, then soared by 56.75% to $15.6 million in 2025, then plunged by 58.5% to $6.5 million in 2026.
- The last three Total Liabilities figures came in at $6.5 million (Q1 2026), $15.6 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | 4.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.99 Mn |
| Mar 31, 2026 | 6.46 Mn |
| Dec 31, 2025 | 15.57 Mn |
| Sep 30, 2025 | 11.57 Mn |
| Jun 30, 2025 | 10.68 Mn |
| Mar 31, 2025 | 10.11 Mn |
| Dec 31, 2024 | 9.93 Mn |
| Sep 30, 2024 | 10.68 Mn |
| Jun 30, 2024 | 9.61 Mn |
| Mar 31, 2024 | 11.36 Mn |
| Dec 31, 2023 | 9.15 Mn |
| Sep 30, 2023 | 27.86 Mn |
| Jun 30, 2023 | 33.62 Mn |
| Mar 31, 2023 | 37.46 Mn |
| Dec 31, 2022 | 2.02 Mn |
| Sep 30, 2022 | 46.29 Mn |
| Jun 30, 2022 | 50.88 Mn |
| Mar 31, 2022 | 54.16 Mn |
| Dec 31, 2021 | 57.70 Mn |
| Sep 30, 2021 | 63.08 Mn |